Is Veracyte Inc (VCYT) overvalued? · P/E 47, rev $289.4M
Veracyte Inc (VCYT) is a diagnostics & research company listed on NASDAQ.
This page asks whether Veracyte Inc (VCYT) looks expensive on cached numbers — not a short thesis.
Latest reported VCYT revenue for 2026-06-30 was $289.4M. Net income was $54.2M. VCYT currently screens at market cap $4.09B and trailing P/E 47.5.
VCYT currently screens at market cap $4.09B and trailing P/E 47.5. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next VCYT 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the VCYT stock page for the full model, not this heading.
Not investment advice.